Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 21, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - December 21, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/21/14 - Alimera Sciences' ILUVIEN Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema
By a News Reporter-Staff News Editor at Marketing Business Weekly Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that the Dutch Inspectie voor de Gezondheidszorg has granted marketing authorization in the Netherlands to...
12/21/14 - GlycoMimetics Updates on University of Michigan Study [Professional Services Close - Up]
GlycoMimetics recently reported that the University of Michigan has dosed the first healthy volunteer in a Phase 1 clinical trial of GMI-1271, a novel and proprietary E-selectin antagonist. The U-M study of our drug candidate as a potential treatment for a serious blood- clotting disorder is an important example of a potential additional indication
12/21/14 - Incyte Gets FDA Approval for Jakafi (ruxolitinib) [Professional Services Close - Up]
Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi, an oral medication, is the first and only product approved by the FDA for PV, a rare and progressive blood cancer.
12/21/14 - Incyte: U.S. Food and Drug Administration Approves Jakafi for Uncontrolled Polycythemia Vera [Professional Services Close - Up]
Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. In a release, the Company noted that PV is a rare and progressive blood cancer. For the first time we are able to provide these pa
12/21/14 - Jazz Pharmaceuticals Enrolls Patients in Xyrem (Sodium Oxybate) Trial [Professional Services Close - Up]
According to a release from Jazz Pharmaceuticals, Xyrem is the only U.S. Food and Drug Administration approved treatment for narcolepsy with cataplexy in adults. "Narcolepsy with cataplexy is a debilitating, chronic condition that commonly begins in childhood, yet there are no approved cataplexy treatments for patients under the age of 18," said J
12/21/14 - Mylan Gets Tentative FDA Approval for Paediatric Formulations of Abacavir/lamivudine [Professional Services Close - Up]
Mylan recently reported that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. Dominique Limet, CEO ViiV Healthcare commented
12/21/14 - PacificGMP Links with Ohio Clinical Trials Collaborative [Manufacturing Close - Up]
"By working closely with the OCTC network, we at PacificGMP believe that our clients will be able to complete their clinical trials faster and more quickly, thus bringing needed therapies, vaccines, and diagnostics to the public," said Gary Pierce, the Chief Executive Officer and General Counsel of PacificGMP. PacificGMP's client pool is largely th
12/21/14 - SAB Biotherapeutics and U.S. Army Team to Treat Hantavirus [Manufacturing Close - Up]
SAB Biotherapeutics, a biopharmaceutical development company, recently teamed with the U.S. Army Medical Research Institute of Infectious Diseases to address the potentially deadly hantavirus using a novel approach to developing protective antibodies against it. Hantaviruses cause a condition known as Hantavirus Pulmonary Syndrome, which has a case
12/21/14 - Seattle Genetics and Takeda Report Data from Adcetris Study [Professional Services Close - Up]
Seattle Genetics and Takeda Pharmaceutical Company Limited recently reported data demonstrating that Hodgkin lymphoma patients at risk of relapse following an autologous stem cell transplant who received Adcetris as consolidation therapy immediately after ASCT had significant improvement in progression-free survival compared to patients who...
12/21/14 - Studies from University of Tennessee Yield New Data on Public Policy (Principles in Action: An Examination of Food and Drug Administration Letters...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Data detailed on Public Policy have been presented. For more information on this research see: Principles in Action: An Examination of Food and Drug Administration Letters Involving Violative Internet Promotions from 1997 to 2012. Journal of Public Policy& Marketing, 2014; 33:
12/21/14 - Sunovion Pharmaceuticals Submits Supplemental Drug Application to FDA for Approval [Professional Services Close - Up]
Sunovion Pharmaceuticals recently reported that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration seeking approval for the use of Aptiom as monotherapy treatment of partial-onset seizures. "Sunovion has a deep commitment to helping address the unmet medical needs of people living with partial-onset seizu
12/21/14 - UCB Selects Cegedim Relationship Management Mobile Intelligence Cloud Platform [Manufacturing Close - Up]
UCB Inc., the U.S.-based subsidiary of UCB S.A. with Headquarter in Belgium, has recently completed the deployment of Cegedim's Customer Relationship Management, Mobile Intelligence and Closed Loop Marketing on Apple's iPad devices, which has allowed for consolidation from three separately sourced applications to one integrated multichannel platfor
12/20/14 - Actavis Considers Offer For Almirall : Report
MADRID- Generic drug maker Actavis plc is considering Spanish drugmaker Almirall SA as one of several possible takeover targets, Bloomberg reported citing people familiar with the matter said. The report said that Actavis has identified Almirall, which could be valued at about 3 billion euros or $3.7 billion in a deal, as one of its preferred targe
12/20/14 - Alimera Sciences' ILUVIEN Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema
By a News Reporter-Staff News Editor at Marketing Weekly News Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that the Dutch Inspectie voor de Gezondheidszorg has granted marketing authorization in the Netherlands to ILUVIEN.
12/20/14 - Cardiff-based pharmaceutical company sets up US subsidiary [Western Mail (Wales)]
The Aim-listed business is moving its operation from London to Cardiff after successfully raising Pounds 14 m in March through a new equity placing- with the cornerstone investor being the Welsh Government's Welsh Life Sciences Investment Fund. The company has incorporated Verona Pharma Inc and also announced the appointment of Kenneth Newman to th
12/20/14 - Firm with over Pounds 13m turnover moves its global HQ to marina ; NEW OCCUPANTS: Pharmaceutical company moors up at multi-million pound development [Derby Evening Telegraph (England)]
A RAPIDLY growing pharmaceutical and healthcare products firm has become the latest business to move into a new multi-million pound development at a Derbyshire marina. Bionical has taken offices at the Boardwalk, a Pounds 1.7 million scheme at Mercia Marina, near Willington. Yesterday, Secretary of State for Transport and Derbyshire Dales MP Patric
12/20/14 - HeartFlow Secures De Novo Clearance from the U.S. Food and Drug Administration for Breakthrough FFRCT Technology
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, announced that it received de novo clearance from the U.S. Food and Drug Administration for its FFRCT technology. HeartFlow FFRCT is the first and only non-invasive imaging technology for
12/20/14 - Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze (asparaginase Erwinia chrysanthemi)
Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze . "Administration of Erwinaze through an intravenous infusion provides physicians another option for patients, including those who cannot tolerate intramuscular injections," said Jeffrey Tobias, M.D., executiv
12/20/14 - MEI Pharma Announces Election of Pharmaceutical Industry Veteran Kevan Clemens to Board of Directors
By a News Reporter-Staff News Editor at Marketing Weekly News MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced the election of Kevan E. Clemens, Ph.D., to its Board of Directors at the Company's Annual Meeting of Stockholders yesterday. His election increases the size of MEI Pharma
12/20/14 - Pharmaceutical Excipients Market: N.A. & Europe to Show Sluggish Growth Says a Latest Research Report Available at RnRMarketResearch.com
DALLAS, Dec. 20, 2014/ PRNewswire-iReach/ The global pharmaceutical excipients market is expected to grow at a CAGR of 6.7% during the forecast period of 2014 to 2019. Swellingutilization of parenteral products owing to rise in the global burden of chronic and lifestyle diseases and heavy investments by the pharmaceutical industry on the developm
12/20/14 - PPMA holds meeting
The meeting was attended by Muhammad Mansoor Dilawar, Khawaj Shahzeb Akram, Ejaz Ahmed Siddiqui, Akbar Ali Bhatti, Uzair Nagra, Khalid Munir, Dr. Zulfiqar Malik, Shafique Abbasi, Dr. Tahir Azam, Shahensah Riasat, Mubashar Javaid, Abid Ali Jawa, Ch. Yousaf Ali, Haseeb Khan, Aamir Saleem Butt, Adeel Haider and other owners of pharma industry.
12/20/14 - Strong reservations: Health Dept criticised for taking action against drug firms
The Pakistan Pharmaceutical Manufacturing Association criticised Punjab Health Department on Friday for taking action against two pharmaceutical companies. Many illegal actions were taken that day including sample collection, compiling a report, calling an urgent meeting of the Provincial Quality Control Board and making unilateral decisions.
12/19/14 - AbbVie Receives U.S. FDA Approval of VIEKIRA PAK? (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK?, an all-oral, interferon-free treatment, with or without ribavirin, for the treatment of patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis. "We are proud of the work of our research and development organization to bri
12/19/14 - Acne Vulgaris - Pipeline Review, H2 2014
Dublin- Research and Markets has announced the addition of the "Acne Vulgaris- Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action, route o
12/19/14 - Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Actavis plc, a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston, MA.. The presentation will take place on Tuesday, January 6, 2015 at 12:00 PM Eastern
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
RxSchool
Medication Errors: A Patient Safety and Quality Improvement Program
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415